Cargando…
Processing Escape Mechanisms Through Altered Proteasomal Cleavage of Epitopes Affect Immune Response in Pulmonary Neuroendocrine Tumors
BACKGROUND: Immunotherapy, especially immune checkpoint inhibition, is one of the most sophisticated approaches in cancer therapy. Immune checkpoint inhibition has already been successfully applied for treatment of non-small cell lung cancer and various other entities. Unfortunately, 60% of the case...
Autores principales: | Wessolly, Michael, Walter, Robert F. H., Vollbrecht, Claudia, Werner, Robert, Borchert, Sabrina, Schmeller, Jan, Mairinger, Elena, Herold, Thomas, Streubel, Anna, Christoph, Daniel C., Eberhardt, Wilfried E. E., Kollmeier, Jens, Mairinger, Thomas, Schmid, Kurt W., Wohlschlaeger, Jeremias, Hager, Thomas, Mairinger, Fabian D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295696/ http://dx.doi.org/10.1177/1533033818818418 |
Ejemplares similares
-
Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro
por: Borchert, Sabrina, et al.
Publicado: (2019) -
A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient’s Suitability for Immune Checkpoint Inhibition
por: Wessolly, Michael, et al.
Publicado: (2020) -
Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy
por: Mairinger, Fabian D., et al.
Publicado: (2018) -
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
por: Walter, Robert F. H., et al.
Publicado: (2018) -
One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy
por: Hager, Thomas, et al.
Publicado: (2023)